Abstract | INTRODUCTION: METHODS: RESULTS: Both ROS and PIT lowered LDL-C and triglyceride, and increased HDL-C. In particular, significantly greater reduction in LDL-C was seen with ROS (-44.1%) than with PIT (-36.9%, P<0.01) in the crossover group from ROS to PIT, and the same result was detected in the crossover group from PIT (-34.8%) to ROS (-44.7%). The ratio of LDL-C/HDL-C was significantly reduced with ROS treatment (from 3.45 to 1.85) compared with that with PIT (from 3.45 to 2.22, P<0.01). Both ROS and PIT lowered plasma levels of high-sensitivity C-reactive protein ( hsCRP), tumor necrosis factor ( TNF)-alpha, and plasminogen activator inhibitor-1 (PAI-1). In addition, the hsCRP level with the administration of ROS was significantly improved compared with the administration of PIT. There was no significant correlation between changes in LDL-C and hsCRP, TNF-alpha, and PAI-1 levels. ROS and PIT did not have an adverse effect on glycemic control in type 2 diabetes patients. CONCLUSION:
Therapy with both statins improved lipid profiles and reduced proinflammatory responses; however, 2.5 mg of ROS have a potent LDL-C-lowering and hsCRP-lowering effect compared with 2 mg of PIT in patients with diabetes.
|
Authors | Kazunori Yanagi, Tsuyoshi Monden, Shiori Ikeda, Mihoko Matsumura, Kikuo Kasai |
Journal | Advances in therapy
(Adv Ther)
Vol. 28
Issue 2
Pg. 160-71
(Feb 2011)
ISSN: 1865-8652 [Electronic] United States |
PMID | 21222064
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Cholesterol, HDL
- Cholesterol, LDL
- Fluorobenzenes
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Plasminogen Activator Inhibitor 1
- Pyrimidines
- Quinolines
- Sulfonamides
- Triglycerides
- Tumor Necrosis Factor-alpha
- Rosuvastatin Calcium
- C-Reactive Protein
- pitavastatin
|
Topics |
- C-Reactive Protein
(analysis)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Cross-Over Studies
- Diabetes Mellitus, Type 2
(complications, drug therapy, metabolism)
- Dose-Response Relationship, Drug
- Drug Monitoring
- Fluorobenzenes
(administration & dosage, adverse effects)
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage, adverse effects)
- Hyperlipidemias
(complications, drug therapy, metabolism)
- Japan
- Plasminogen Activator Inhibitor 1
(blood)
- Pyrimidines
(administration & dosage, adverse effects)
- Quinolines
(administration & dosage, adverse effects)
- Rosuvastatin Calcium
- Sulfonamides
(administration & dosage, adverse effects)
- Treatment Outcome
- Triglycerides
(blood)
- Tumor Necrosis Factor-alpha
(blood)
|